Description: President Trump is expected to unveil plans to lower healthcare costs, which could significantly impact the pharmaceutical industry. Additionally, Pfizer's (PFE) entry into the weight-loss drug space, joining Novo Nordisk (NVO) and Eli Lilly (LLY), will also likely make waves. Yahoo Finance Senior Reporter Brooke DiPalma and Yahoo Finance Senior Business Reporter Ines Ferré join Opening Bid host Brian Sozzi to take a closer look at one frequently overlooked pharmaceutical name: Moderna (MRNA). To watch more expert insights and analysis on the latest market action, check out more Opening Bid.

Description: Vaccine-maker Moderna has become the most shorted company in the S&P 500, with its share price slumping to its lowest level since before the...

Description: Moderna’s stock has seen a notable shift in sentiment after its fair value estimate was cut from $40.30 to $37.32. This change reflects revised expectations for the company's long-term potential. The adjustment comes as revenue growth projections have been reduced from 18.75% to 10.31%, with analysts weighing bullish signals against lingering macro and operational challenges. Stay tuned to discover how investors can stay ahead of these evolving perspectives on Moderna's future...

Description: A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to

Description: Health care stocks declined late Thursday afternoon with the NYSE Health Care Index and the Health C

Description: The initiative forms part of Moderna’s continued investment in US-based infrastructure.

Description: Moderna’s nearly $20 billion cash hoard has dwindled to a single-digit stash following a series of setbacks for the biotech.

Description: Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 Expects to expand seasonal vaccine franchise from three to up to six approved products by 2028 Targets readouts from nine ongoing Phase ...

Description: Non-dilutive financing from premier lender bolsters strong balance sheet and provides increased flexibility Company reiterates 2025 financial guidance provided on 3Q25 earnings call and targets cash breakeven by 2028 CAMBRIDGE, MA / ACCESS Newswire ...

Description: At an analyst day event, Moderna said it wants to invest revenue from a hopefully expanded seasonal vaccine franchise into oncology and rare disease programs, to “set the stage for additional growth in 2027 and 2028.”

Description: Health care stocks fell late Wednesday afternoon with the NYSE Health Care Index easing 0.1% and the

Description: Health care stocks traded mixed Wednesday afternoon, with the NYSE Health Care Index up 0.1% and the

Description: Moderna’s nearly $20 billion cash hoard has dwindled to a single-digit stash. Following a series of setbacks for the biotech, investors are shifting focus to its cancer pipeline.

Description: For the first time, security, IT and IAM teams can manage AI agent identities from discovery to deprovisioning to eliminate blind spots, enforce least privilege, and secure the next evolution of identity and access management NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Token Security, the leader in Agentic Identity security, today announced new AI Agent Identity Lifecycle Management capabilities which empower enterprises to discover, govern, manage, and secure the rapidly growing population of A

Description: New capabilities strengthen U.S. production, completing Moderna's domestic end-to-end mRNA manufacturing network More than $140 million investment will create hundreds of highly skilled biomanufacturing jobs CAMBRIDGE, MA / ACCESS Newswire / November ...

Description: A bipartisan report warned Congress about China’s growing control over the pharmaceutical supply chain. Elsewhere, Alkermes sweetened its bid for Avadel and Moderna is investing $140 million in U.S. drug production.

Description: CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / November 18, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference: Piper Sandler's 37th Annual Healthcare Conference, on Tuesday, December ...

Description: Pfizer CEO Albert Bourla told Yahoo Finance that Pfizer has a "right to win" on the obesity drugs that have become a major market.

Description: Moderna’s third quarter was shaped by sharply lower demand for COVID-19 vaccines, yet the company delivered results above Wall Street expectations for both revenue and earnings. Management attributed the outperformance to rigorous cost discipline, with CEO Stéphane Bancel noting a 34% reduction in combined cost of sales, R&D, and SG&A compared to last year. The company also cited strong market uptake of its new COVID vaccine, mNEXSPIKE, and the impact of ongoing productivity initiatives. CFO Jam

Description: The main US stock measures were pointing higher in Wednesday's premarket activity as traders await a

Description: OXFORD, United Kingdom, November 10, 2025--A major new regional partnership, Equinox (Equitable Innovation Oxford) has officially launched to establish Oxford as a global centre for innovation and entrepreneurship.

Description: Are Wall Street analysts favoring Moderna’s stock?

Description: In the past week, Moderna reported third-quarter 2025 earnings with revenue at US$1.02 billion, down sharply from the previous year, alongside a net loss of US$200 million and lowered full-year revenue guidance to US$1.6–2 billion. An interesting detail is that, while COVID vaccine demand softened and Moderna discontinued its CMV vaccine development, the company maintained cost reductions and advanced key regulatory filings and product launches. To assess how these developments impact...

Description: As you might know, Moderna, Inc. ( NASDAQ:MRNA ) just kicked off its latest quarterly results with some very strong...

Description: Third quarter earnings season is in full swing, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.

Description: Health care stocks edged lower late Friday afternoon, with the NYSE Health Care Index shedding 0.1%

Description: Health care stocks declined Friday afternoon, with the NYSE Health Care Index and the Health Care Se

Description: Moderna (MRNA) continues to target cash breakeven in 2028, banking on its ongoing cost reductions an

Description: Moderna’s stock narrative has experienced a notable shift following recent analyst updates. The consensus fair value is holding steady at $40.30, and revenue growth projections have moved sharply higher. Analysts point to evolving developments in Moderna’s clinical pipeline and a slightly increased discount rate as key drivers of the changed outlook. However, views remain mixed on the company’s near-term prospects. Stay tuned to discover how investors can monitor emerging trends that could...

Description: India's Coronavirus Vaccine Market offers growth through government-led initiatives, robust manufacturing, and R&D in vaccine types. Opportunities arise from vaccine diplomacy, expanding healthcare in Tier 2 and 3 cities, and innovations like mRNA technology. Challenges include vaccine hesitancy and misinformation. Indian Coronavirus Vaccine Market Indian Coronavirus Vaccine Market Dublin, Nov. 07, 2025 (GLOBE NEWSWIRE) -- The "India Coronavirus Vaccine Market, By Region, By Competition, Opportu

Description: Biotechnology company Moderna (NASDAQ:MRNA) reported revenue ahead of Wall Streets expectations in Q3 CY2025, but sales fell by 45.4% year on year to $1.02 billion. On the other hand, the company’s full-year revenue guidance of $1.8 billion at the midpoint came in 4.4% below analysts’ estimates. Its GAAP loss of $0.51 per share was 78.6% above analysts’ consensus estimates.

Description: Third quarter earnings season is in full swing, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.

Description: Moderna stock surged Thursday after the Covid vaccine-maker significantly cut its third-quarter costs, and still managed to easily beat sales expectations.

Description: The major gauges have reached a holding pattern in a volatile week with investors seeking firm news on tariffs, earnings and Tesla.

Description: Yahoo Finance anchor Josh Lipton recaps three of the top stories investors are watching as part of Yahoo Finance's Market Minute, including Vistra's (VST) revenue miss, Moderna's (MRNA) narrower-than-expected loss, and Tapestry's (TPR) weak outlook. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.

Description: Moderna Inc (MRNA) navigates a challenging quarter with significant cost reductions and strategic partnerships, despite a decline in COVID vaccine demand.

Description: MRNA posts narrower-than-expected Q3 loss and lifts liquidity outlook for 2025, as cost cuts and revised spending plans boost investor sentiment

Description: Moderna’s third-quarter results weren’t as bad as they could have been, which was enough to trigger a rally in the stock on Thursday. Sales of Moderna’s respiratory syncytial virus, or RSV, vaccine remain negligible, and the company had a net loss of $200 million for the quarter. The quarter’s revenue of $1 billion beat the FactSet consensus estimate of $900 million.

Description: Moderna (MRNA) narrowed its full-year revenue outlook on Thursday as the drugmaker's third-quarter t

Description: Moderna shares rose after the company posted a narrower third-quarter loss than Wall Street expected, a sign that its cost-cutting measures are helping offset the decline of its Covid business. Gerry Smith reports on "Bloomberg Open Interest."

Description: The company posted a net loss of 51 cents a share, against Wall Street’s expectation for a loss of $2.21. Moderna has aggressively reduced costs through measures including staff cuts and lower spending on research and manufacturing to offset slowing vaccine sales. The company still has a goal of breaking even by 2028, Moderna Chief Financial Officer Jamey Mock said in an interview.

Description: The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.2% and the actively trad

Description: Moderna (MRNA) delivered earnings and revenue surprises of +76.28% and +18.13%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: Biotechnology company Moderna (NASDAQ:MRNA) beat Wall Street’s revenue expectations in Q3 CY2025, but sales fell by 45.4% year on year to $1.02 billion. On the other hand, the company’s full-year revenue guidance of $1.8 billion at the midpoint came in 4.4% below analysts’ estimates. Its GAAP loss of $0.51 per share was 78.6% above analysts’ consensus estimates.

Description: Investing.com - Moderna has reported a sharp drop in third-quarter revenue, but still topped Bloomberg consensus estimates, while the drugmaker also trimmed its full-year sales forecast.

Description: MRNA) on Thursday reported a loss of $200 million in its third quarter. On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 51 cents. The results exceeded Wall Street expectations.

Description: Despite quarterly revenue totals that were nearly cut in half compared to the same period last year, Moderna still expects to break even financially in 2028 with the help of more disciplined spending.

Description: Moderna swung to a loss and logged lower sales in the third quarter as it works to expand its offerings amid weakening demand for its Covid-19 vaccine.

Description: Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected revenue range to $1.6 - $2.0 billion Improves 2025 expected GAAP operating expenses by $0.7 billion to a range of $5.2 - ...

Description: The major gauges have reached a holding pattern in a volatile week with investors seeking firm news on tariffs, earnings and Tesla.

Description: Moderna reports earnings early Thursday as investors wonder whether the biotech will run through its pandemic-era windfall before it stops losing money. The vaccine company had accumulated nearly $20 billion in cash by early 2022, thanks to the record-smashing sales of its Covid-19 shot, but has been losing billions of dollars a year since 2023. Management has said Moderna will have $6 billion left at the end of this year, will stop losing money in 2028, and won’t need to raise any new cash to bridge the gap.

Description: The nucleic acid therapeutics market is growing due to rising genetic and chronic disease prevalence, expanding genomics R&D, and increased RNA therapeutics adoption. Key opportunities include precision medicine demand, mRNA applications, advanced delivery platforms, AI integration, and regulatory support. Nucleic Acid Therapeutics Market Nucleic Acid Therapeutics Market Dublin, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The "Nucleic Acid Therapeutics Market Report 2025" has been added to ResearchAndMark

Description: Biotechnology company Moderna (NASDAQ:MRNA) will be reporting results this Thursday before the bell. Here’s what investors should know.

Description: Moderna (MRNA) just began dosing patients in a Phase 1/2 study of mRNA-2808, its experimental T-cell therapy for advanced multiple myeloma. This effort highlights Moderna's growing emphasis on cancer research as it moves beyond COVID-19 vaccines. See our latest analysis for Moderna. Despite excitement over cancer-vaccine partnerships and high-profile buyout speculation, Moderna’s share price return is down 40.7% year-to-date. This reflects a tough run as investors reassess risk after mixed...

Description: MRNA is likely to have faced earnings pressure and pipeline setbacks as waning COVID-19 vaccine demand weighs on its outlook.

Description: Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 6.9% in the afternoon session after ongoing concerns about its financial performance and a recent clinical setback overshadowed an announcement about a new, early-stage study.

Description: CAMBRIDGE, MA / ACCESS Newswire / November 3, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the Company's investigational mRNA-based T-cell engager (TCE) for participants ...

Description: George Tidmarsh’s short run directing the agency’s principal drug review office reportedly ended in controversy. Elsewhere, Moderna advanced a T-cell engager and Lilly expanded a production push for its GLP-1 pill.

Description: Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.5% in the afternoon session after the stock retreated, giving back some of the strong gains from the previous session that were fueled by reports of potential buyout or partnership discussions.

Description: Recently, Zacks.com users have been paying close attention to Moderna (MRNA). This makes it worthwhile to examine what the stock has in store.

Description: Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Description: A social media giant faltered on Thursday, Oct. 30, 2025, as a tax event weighed on its results, while a biotech name benefitted from reports of talks with a major pharma player.

Description: Investing.com -- Moderna (NASDAQ:MRNA) stock surged as much as 12% Thursday following a STAT News report that the COVID-19 vaccine maker has been in discussions with at least one large pharmaceutical company about "a deal of significant scope," which could include a potential acquisition.

Description: Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.

Description: When the S&P 500 is rallying to all-time highs, you have to wonder about the stocks getting left out. Turns out analysts see great promise.

Description: BOSTON, October 27, 2025--Harvard Business Review announces final lineup for Future of Business 2025, its Nov. 3 virtual conference featuring top global leaders and thinkers.

Description: Moderna (MRNA) reached $26.74 at the closing of the latest trading day, reflecting a +1.87% change compared to its last close.

Description: Moderna announced in October 2025 that it will discontinue development of its investigational cytomegalovirus (CMV) vaccine, mRNA-1647, following disappointing results from a Phase 3 clinical trial that did not meet its primary efficacy endpoint in seronegative women of childbearing age. This decision marks a setback for one of Moderna’s most advanced late-stage programs, highlighting the ongoing risks and volatility inherent in late-stage vaccine development. We’ll assess how discontinuing...

Description: Moderna stock toppled Thursday after the biotech company's experimental CMV vaccine failed in a Phase 3 study of 7,500 women.

Description: Health care stocks were mixed late Thursday afternoon, with the NYSE Health Care Index shedding 0.1%

Description: CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2025 Top Employers Survey for the eleventh consecutive ...

Description: Health care stocks edged lower Thursday afternoon, with the NYSE Health Care Index easing 0.1% and t

Description: Yahoo Finance senior reporter Allie Canal keeps track of several Wall Street analyst calls on top trending stocks, including calls around shares of Tesla (TSLA), Zions Bancorporation (ZION), and Moderna (MRNA). To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.

Description: CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host its Investor Event - Analyst Day at 9:00 a.m. ET on Thursday, November 20, 2025. The event will include presentations from management ...

Description: Moderna is expected to announce its third-quarter results next month, and analysts expect a significant loss per share.

Description: Moderna (MRNA) closed at $26.85 in the latest trading session, marking a -2.33% move from the prior day.

Description: A shot analysts projected as a multibillion-dollar seller produced results “well below” the company’s expectations, heightening pressure on Moderna’s flagging respiratory vaccine business.

Description: Moderna is stopping development of a vaccine designed to prevent birth defects caused by cytomegalovirus, or CMV, once among its most-watched experimental programs. CMV infections generally don’t cause symptoms in adults, but babies who contract the virus during pregnancy can suffer long-term health effects. The Moderna jab would have needed to fully prevent infections in pregnant mothers, not just tamp down symptoms, to protect infants from birth defects.

Description: Company to discontinue development of mRNA-1647 in congenital CMV Company will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in bone marrow transplant patients Company does not anticipate any impact to its 2025 financial guidance or its ...

Description: The biotech's innovative qualities will come in handy.

Description: This live blog is refreshed periodically throughout the day with the latest updates from the market.To find the latest Stock Market Today threads, click here. Happy Wednesday. This is TheStreet’s Stock Market Today for Oct. 22, 2025. You can follow the latest updates on the ...

Description: Shares could keep sliding, as Moderna's post-COVID pipeline has yet to reach a breakthrough.

Description: Moderna’s story is far from over, but it needs patience and successful execution.

Description: Don't try to catch a falling surgical knife.

Description: The 221-acre site sits next to the Harwell Science and Innovation Campus in Oxfordshire.

Description: Moderna (MRNA) shares have been volatile lately, drawing fresh attention as investors weigh the company’s prospects beyond COVID-19 vaccines. With its next earnings report approaching, the market is watching for signs of future growth. See our latest analysis for Moderna. After a tough stretch for Moderna, the share price has slid 38% year to date, and the total shareholder return over the past year is even deeper in the red at -52%. Some short-lived rallies have popped up, but recent price...

Description: Super Micro Computer stock was on pace to end Monday’s session as the top performer in the index, as bullish attitudes on Wall Street lifted shares higher. The stock snapped a two-day losing streak and rose 6.3% to $55.65, hovering below its 52-week high of $66.44. Super Micro, which makes servers and storage products for data centers, falls into the broader category of artificial intelligence-linked names that have seen explosive gains lately.

Description: The Dow Jones index was up Monday but lagged the Nasdaq. Cleveland-Cliffs soared on the stock market today. Amazon rose amid an AWS outage.

Description: Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.

Description: CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced data regarding two of its investigational influenza candidates will be presented at IDWeek 2025, October 19-22, 2025, in Atlanta, GA. The details of the ...

Description: Moderna (MRNA) shares were down almost 5% in recent trading on Friday after management provided an u

Description: Moderna Inc. (NASDAQ:MRNA) is one of the best high volume stocks to buy according to Wall Street analysts. On October 13, Moderna announced that promising clinical, safety, and translational data from its Phase 1/2 study evaluating the investigational immune-evasion targeted cancer antigen therapy/CAT mRNA-4359 would be presented at the 2025 European Society for Medical Oncology/ESMO […]